ArticleWorld journal of gastrointestinal pharmacology and therapeutics2025
Real-world effectiveness and safety of teduglutide in adult and pediatric patients with short bowel syndrome in Argentina.
Article in World journal of gastrointestinal pharmacology and therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Real-world effectiveness and safety of teduglutide in patients with short bowel syndrome.World journal of gastrointestinal pharmacology and therapeutics · 2026Article
- Optimizing teduglutide treatment regimens in children with short bowel syndrome.Frontiers in pediatrics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundApproval of teduglutide is an important addition to the limited treatment options for short bowel syndrome (SBS). However, real-world evidence on teduglutide therapy for SBS in Latin America is scarce.
aimTo investigate the effectiveness and safety of teduglutide in clinical practice in Argentina with a 24-week follow-up.
methodsThis non-interventional multicentre cohort study included consecutive patients (aged ≥ 1 years) with SBS who were dependent on parenteral support (PS) and received ≥ 1 dose of teduglutide according to currently approved indications.
resultsThe study population (
conclusionThis prospective real-world study demonstrated the effectiveness and safety of teduglutide in adult and pediatric patients with SBS in Argentina. The clinical response observed in both adults and pediatric patients was greater than that reported in phase 3 trials and was consistent with the results of other real-world studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.